|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 741 USD | +1.32% |
|
-0.50% | +27.46% |
| 05:55pm | Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple... |  |
| 12:00pm | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
Nov 19 (Reuters) - The U.S. Food and Drug Administration on Thursday approved emergency use of Eli Lilly and Co's antibody drug baricitinib, in combination with remdesivir, to treat COVID-19 patients.
The drug was authorized for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring oxygen support. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)
| 1st Jan change | Capi. | |
|---|---|---|
| +27.46% | 659B | |
| +27.68% | 557B | |
| -4.24% | 359B | |
| +16.66% | 322B | |
| +9.85% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.79% | 149B | |
| -5.08% | 146B |
ELI LILLY AND COMPANY 
